Breast cancer (early) - hormonal treatments
Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
| Guidance type:
Technology appraisal
|
| Date issued:
November 2006
|
We will consult on our review plans for this guidance in June 2009. |
| Reference:
TA112 |
Summary
Anastrozole, exemestane and letrozole are recommended as possible treatments for women who have a type of breast cancer called early oestrogen-receptor-positive breast cancer and have been through the menopause. Anastrozole, exemestane or letrozole may be given as an 'extra' treatment (called an adjuvant treatment), after the woman has had an operation to remove the cancer, to help to stop the cancer coming back.
|
| Top |
Documents
For healthcare professionals
For patients, carers and the public
Background information
|
Implementing this guidance
Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:
|
| Top |
